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Rosai—Dorfman disease is an uncommon benign proliferation
of hematopoietic and fibrous tissue. Its initial manifestations
most often include a roughly symmetric, painless, bilateral
cervical adenopathy, fever, leukocytosis, and hypergamma-
globulinemia, although extranodal disease may develop.1—3
Rosai—Dorfman disease in HIV-infected patients has been
previously reported in just three cases.4—6 We report herein
the case of a young Venezuelan woman, recently diagnosed
with HIV, who had developed Rosai—Dorfman disease with
maxillary and malar involvement.
A 56-year-old woman was evaluated at the ear, nose and
throat (ENT) service with a three-year history of hard palate
swelling with compromise of the right genian region. Physical
examination revealed a volume increase in the right side of
the face. A considerable hard palate swelling was observed.
Laboratory studies on presentation revealed HIV infection
(HIV-1 and -2 ELISA tests were positive, and infection was
confirmed with the Western-blot test). Multiple lesion biop-
sies were undertaken. Other laboratory studies were per-
formed; no alterations in complete blood count or chemistry
were evidenced. Serology for Coccidioides immitis, hepatitis
B virus, Epstein—Barr virus (EBV), and cytomegalovirus were
positive. The CD4 cell count was 350 cells/ml and the viral
load was 10 000 copies of RNA/ml. CT-scans showed a sig-
nificant compromise of the soft tissues in the right maxillary
region (including a significant compromise of bone struc-
tures). A subtotal therapeutic maxillectomy and biopsy were
carried out. The maxillary antrum lateral wall was found to
have fibrohistiocytic lesions and inflammatory changes. In
the resected tissues, a significant number of large, pale
histiocytic cells that contained apparently engulfed lympho-
cytes or plasmocytes within their cellular borders was
observed (emperipolesis; Figure 1). These distinctive large,
pale cells — Rosai—Dorfman cells — were S-100 protein-positive by immunostaining and so differ from ordinary his-
tiocytes (Figure 1). CD68 immunohistochemistry was also
positive.
Most cases of Rosai—Dorfman disease occur during the
first or second decade of life, but any age group can be
affected. The youngest patient on first series had congenital
sinus histiocytosis with massive lymphadenopathy (SHML),
and the oldest developed symptoms at age 74.7,8 However,
Rosai—Dorfman disease in HIV-infected patients has been
previously reported in just three cases,4—6 thefirst described
in 1991. To our knowledge, this case is the fourth to be
reported. Microscopically, there was a pronounced dilata-
tion of the lymph nodes (see Figure 1). The sinuses were
occupied by numerous histiocytic cells with a large vesicular
nucleus and abundant clear cytoplasm, which may contain
lipids and also lymphocytes and plasma cells. The histolo-
gical key feature of Rosai—Dorfman disease is the presence
of various numbers of large, pale histiocytic cells that con-
tain within their cellular borders apparently engulfed lym-
phocytes or plasmocytes (emperipolesis); these distinctive
large, pale cells — Rosai—Dorfman cells — are S-100 protein-
positive by immunostaining and so differ from ordinary
histiocytes.
Despite its sometimes impressive clinical presentation,
Rosai—Dorfman disease is a benign and self-limiting disease,
whose treatment is aimed largely at controlling local mani-
festations (most often by surgical therapy). The microscopic
differential diagnosis, particularly in extranodal disease, is at
times challenging and can include Langerhans cell histiocyto-
sis, Hodgkin’s disease, non-Hodgkin’s lymphoma, metastatic
carcinoma, and metastatic malignant melanoma. Rosai—Dorf-
man disease with maxillary compromise has been previously
reported in four cases (non HIV-infected patients),9—12 and no
cases have been reported with malar compromise. In Vene-
zuela, the first case of primary osseous Rosai—Dorfman disease
was observed by us in 2002,13 and to the best of our knowledge
this pathology has not been reported again until our current
case.
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Figure 1 Histopathological evaluation. (a) Histiocytes in sinus
histiocytosis with massive lymphadenopathy (SHML) with vesi-
cular nuclei and lymphocytophagocytosis (H&E 200). (b) Multi-
nucleated histiocytes with prominent lymphocytophagocytosis
or emperipolesis. The internalized lymphocytes are located in an
optically clear space or cytoplasm vacuoles (H&E 400). (c) S-
100 protein in SHML cells staining strongly positive, diagnostic for
Rosai—Dorfman disease (400).Although numerous case reports concerning Rosai—Dorf-
man disease have been reported in the literature, few have
documented an association with HIV/AIDS. Unfortunately, a
consistent etiology for Rosai—Dorfman disease has not yetbeen found. Immunological relations between Rosai—Dorf-
man disease and viral infections (human herpesvirus 6 (HHV6)
and EBV) have been suggested to explain its etiology;14 HIV
could also be one such viral infection.4 Immunopathology of
Rosai—Dorfman disease could be linked to viral infections
that can create an immunologic environment that will result
in the activation of the histiocyte—macrophage system. In
this disease the immunohistochemical profile is similar to
that of activated macrophages derived from circulating
monocytes stimulated by T-lymphocytes following an immu-
nologic challenge.5,14,15 Other studies have indicated that
this immunological disturbance is associated with a chronic,
but non-specific, infectious state,16 the result of which could
reflect an alteration in the process by which histiocytes
contact T-lymphocytes for antigen presentation.17,18
The current interpretation of the immunostaining profile
of Rosai—Dorfman disease is that SHML cells are functionally
activated macrophages, perhaps recently derived from
monocytes.15 Related pathologies have already been
described in association with HIV, occurring in reactive his-
tiocytosis with hemophagocytosis or in malignant histiocy-
tosis.19,20 In the past, Rosai—Dorfman disease associated with
HIV infection has been described as coincidental because it
has rarely been reported.4 But, whether or not related, some
evidence supports the hypothesis of a relationship between
the disease and HIV infection, as has been suggested in cases
involving HHV6 or EBV. Immune-mediated diseases, asso-
ciated with or preceding Rosai—Dorfman, are not rare.4,15
In some studies, about 12% of the patients with this pathology
had clinical evidence of one or more immune disorders.12 As
was suggested in the first report of an association, we believe
that Rosai—Dorfman disease does represent an HIV-asso-
ciated disease and should be further and more thoroughly
studied; it should also be considered in the differential
diagnosis of tumors complicating HIV infection.
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malarial treatment with artesunate
There are about 300—600 million episodes of clinical Plas-
modium falciparum infections globally every year.1 Malaria
remains a major cause of morbidity and mortality in tropical
countries. Because of the relentless increase in resistance of
malaria parasites to conventional drugs, including chloro-
quine, sulfadoxine—pyrimethamine, and mefloquine, new
therapeutic approaches have been developed. The key one
among these has been artemisinin-based combination ther-
apy (ACT).2,3
The artemisinin group of drugs was discovered in China
from a crude extract of the wormwood plant Artemisia
annua (qinghao).4 Artemisinin is the parent compound thatcan be variedly modified at the C10 position to produce
artesunate, artemether, arteether, dihydroartemisinin, or
artelinic acid. Artesunate is a water-soluble hemisuccinate
derivative of dihydroartemisinin. The hemisuccinate group
in the molecule confers water solubility and relatively high
oral bioavailability. Artesunate is highly active against both
the sexual and asexual forms of the four species of Plas-
modium that affect humans.5 The antimalarial action of
artemisinins has been attributed to their ability to generate
free radicals. The endoperoxide moiety, which is essential
for antimalarial activity, is believed to generate free radi-
cals within the parasites. These free radicals form covalent
bonds with key parasite proteins, such as membrane trans-
porters, thereby impairing their functions.6 However, an
alternative mechanism of action based on inhibition of the
calcium ATPase (sarcoplasmic endoplasmic reticulum cal-
